Cannabis stock news for investors

Friday, 16 October 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 483-Review of two years as we approach the anniversary of legalization in Canada

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 483-Review of two years as we approach the anniversary of legalization in Canada

Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland

Delta, Kelowna, BC, October 16, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/101620-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10161Review-2years-Anniversary-Legalization-Canada.asp

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

In today’s podcast we take a quick look at the last two years of legalization as we approach the anniversary of legalization in Canada.

Year 1 - Obstacles and Accomplishments:

Legalization in Canada came about "to keep cannabis out of the hands of youth, to keep profits out of the pockets of criminals, and to protect public health and safety by allowing adults access to legal cannabis."

Over these past two years we have seen the many obstacles placed on the cannabis industry by un-informed regulators, slow license processing as well as difficulties maintaining quality and consistency at scale.

In the first year, Cannabis 1.0, two of the largest factors impeding the industry's success in Canada were the lack of retail infrastructure as well as the many issues with quality and supply from producers.

While provinces like Alberta, Saskatchewan and Manitoba helped streamline retail licensing and build out their cannabis infrastructure by not limiting their license numbers, Canada’s more populous provinces of BC, Ontario and Quebec were slow to grant licenses and had heavy restrictions and costs for start ups which discouraged growth in the first year.

This in turn kept the illicit market running strong especially in BC and Ontario where delivery options weren’t available and purchases needed to be made directly through the government website or stores. The limited amount of retail infrastructure and government control of the retail sector also affected pricing which in turn also helped to boost illicit sales.

This inconsistency in retail development also caused issues with supply chains between provinces with some provinces running out of the product in short order and being stuck with empty shelves while others were stuck with unwanted stock that degraded to an unsellable quality.

The governing body of Health Canada was also heavily overwhelmed in its first year which left the medical side of the industry mostly abandoned for the recreational market as well as causing delays in products hitting shelves. These delays again led to product degradation and in the first year most products hitting shelves were poorly received by consumers who consistently commented on the dryness of the product, lack of terpenes, poor value perception and many issues with packaging.

While these obstacles may have slowed the progress of the industry, many producers were able to overcome these challenges and learned to adapt by concentrating more on their pre-rolls and larger format dry flower, we saw prices come down to more reasonable standards, and we started to see the premium flower category open up.

Year 2 - Cannabis 2.0 VS COVID:

The last year began with a heavy focus on the potential of Cannabis 2.0 products which had strong momentum, which was quickly slowed by COVID-19.

Now while the COVID pandemic certainly had negative impacts on the cannabis sector such as large scale layoffs, development stalls and supply chain issues we also saw some massive benefits come from this same pandemic.

One of the largest impacts to this industry over the last year is assuredly the fact that in many states and throughout Canada, cannabis businesses were deemed “essential businesses” and were allowed to continue operations so long as they followed proper safety protocols. This change from a fringe industry years before to essential during a pandemic has been the most impactful to the removal of the stigma surrounding cannabis and has helped change the perception of many from “drug” to “medicine”.

Two other great benefits that came from COVID were the mass adoption of new technology platforms and retail forms as well as a great opportunity for R & D. With new restrictions put in place regarding social distancing and contactless payment, many of the technology platforms and online developments that were being slowly adopted in small phases took a massive boost and went from novelty to essential. Few retail stores had curbside pickup, delivery, online sales, online customer service or touchless payment options in store in year one, yet now at the end of this year this is a must have for your business to survive.

In the first year due to supply and demand issues product development and research took a back seat to bulk production whereas in year two we’ve seen a much heavier focus on quality and premium products, new formats and formulations and much more realistic understanding of consumer demands and preferences. While beverages have still been somewhat slow with regards to bringing products to market the overall Cannabis 2.0 market has grown expansively over this last year.

One other great improvement in the Canadian market this last year was the full implementation of the Medical Cannabis by Shoppers Program which finally helped better serve the medical community in Canada and has become a great template for medical programs globally.

Year 3 - What’s Next:

From possible federal regulatory changes in the US to global expansion of the cannabis supply chain to potential record cannabis retails sales globally, the next year in Cannabis has a lot of speculation and excitement surrounding it.

Many key dominos fell into place in the international community this year with new import and export licences granted, more markets opening up to medicinal or recreational cannabis and again because of COVID, international shipping and supply chains are nore more adaptive and fluid than they’ve ever been before.

In Canada and the US many are expecting another year of record setting sales, especially now that there are far more product skus and formats available, the retail and supply chain infrastructure is much more streamlined and built out and access to cannabis has never been simpler with delivery, curbside pickup and contactless payments all available.

While it is well known that this has been an industry that’s been negatively impacted many times by over speculation there is more optimism going into this October 17th then the two previous by all available metrics. It’s going to be a good year for green.

Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

New #Stocks to watch - Biotech (NasdaqGS: $KTRA), Mining (TSX: $MKO.V), Energy (NYSE American: $INDO), eSport (CSE: $GSQ.C), Cannabis (CSE: $CBDX.C), Cleantech (NasdaqGS: $BHTG)

New #Stocks to watch - Biotech (NasdaqGS: $KTRA), Mining (TSX: $MKO.V), Energy (NYSE American: $INDO), eSport (CSE: $GSQ.C), Cannabis (CSE: $CBDX.C), Cleantech (NasdaqGS: $BHTG)

Point Roberts WA, Delta BC, October16, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch. Today’s stocks in Biotech, Mining, Energy, eSport, Cannabis, Cleantech, Tech and Real Estate have been added to our list of free stock directories in each sector.

Read this in full at https://www.investorideas.com/news/2020/main/10161Stocks.asp

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

This week’s new biotech companies are involved in biotechnologies, genetics, pharmaceutical, medical device, life sciences, healthcare, health care and COVID-19 research.

The latest mining companies are both listed on the TSX Venture Exchange while the latest cannabis and gaming companies are listed on the Canadian Stock Exchange (CSE).

The newest cleantech company is involved in waste management, including waste-to-energy and the newest energy company operates in Indonesia.

Finally, the latest real estate company operates in China and the latest tech company is based in India.

New Stocks added to Biotech stocks directory:

Kintara Therapeutics, Inc. (NasdaqGS:KTRA) is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC). VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM. Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.

Neubase Therapeutics, Inc. (NasdaqGS:NBSE) is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

OncoCyte Corporation (NYSE American:OCX) is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company’s proprietary tests and pharmaceutical company services aim to save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while driving the growth of its revenue. Oncocyte recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint inhibitor immunotherapies. The Company’s pharmaceutical company services help pharmaceutical companies to develop new cancer treatments, many of which may be linked to Oncocyte’s diagnostic tests.

Lineage Cell Therapeutics, Inc. (NYSE American:LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer and in preclinical development for additional cancers and as a vaccine against infectious diseases, including SARS-CoV-2, the virus which causes COVID-19

Predictive Oncology Inc. (NasdaqGS:POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. TumorGenesis, Inc. a wholly owned subsidiary specializes in media’s that help cancer cells grow and retain their DNA/RNA and proteomic signatures providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. In addition, TumorGenesis is developing a ‘biomarker discovery’ kit and service for life science, pharmaceutical and biotech companies, and research institutions. Its products are sold on-line as well as through a global distributor; US Biologicals Corporation: http://www.usbio.net. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Biotech brings transformational technology to formulation development for protein-based pharmaceutical and vaccines. In addition, our solubilization & stability technology supports fundamental protein research at academic, pharmaceutical and government laboratories

Greenbrook TMS NeuroHealth Centers (TSX:GTMS.TO) Operating through 125 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation ("TMS") therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 500,000 TMS treatments to over 14,000 patients struggling with depression.

HealthWarehouse.com, Inc. (OTC:HEWA) is America's Leading Online Pharmacy and a pioneer in affordable healthcare. Based in Florence, Kentucky, the Company's services are available nationwide, shipping FDA approved prescription medication and over-the-counter products direct to patients' doors. As one of the first National Association of Boards of Pharmacy ("NABP") Accredited Digital Pharmacies, HealthWarehouse.com services the mission of providing affordable healthcare and incredible patient services to help Americans in all 50 states.

Nova Leap Health Corp (TSXV:NLH.V) s an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centred focus, particularly those requiring dementia care. Nova Leap achieved the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 7 different U.S. states within the New England and South- Central regions as well as Nova Scotia, Canada.

Calmare Therapeutics (OTC:CTTC) researches, develops and commercializes chronic, neuropathic pain devices. Our flagship medical device – the Calmare® Pain Therapy Device (the "Calmare Device") – is the world's only non-invasive, non-addictive modality that can successfully treat chronic, neuropathic pain. The Company holds a U.S. Food & Drug Administration 510k clearance designation on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United States and throughout the world. The Calmare Devices are commercially sold to medical practices and found in U.S. military hospitals, clinics and installations..

Plus Therapeutics, Inc. (NasdaqCM:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.

Joint Chiropractic,The (NasdaqGS:JYNT) revolutionized access to chiropractic care when it introduced its retail business model in 2010. Today, the company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With more than 550 locations nationwide and over seven million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry

Volition RX Ltd (NYSE American:VNRX) is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

Newscope Capital Corporation (CSE:PHRM) is focused on drug repurposing with artificial intelligence. The Company’s drug repurposing artificial intelligence platform combines multilayered processes for integrating millions of data points and performing machine learning to discover new uses of drugs. Wholly-owned subsidiary Pharmather Inc. was founded in 2020 with a particular focus on repurposing ketamine and psilocybin for neurological and pain disorders. The goal is to advance the development of panaceAI™, our drug repurposing AI platform, validate psilocybin in pre-clinical models of stroke and traumatic brain injury, and conduct clinical studies with ketamine for Parkinson’s disease and other disorders of the brain and nervous system.

New stocks added to Mining stocks directory:

Goldmoney Inc. (TSX:XAU.TO) is a precious metal focused global business. Through its ownership of various operating subsidiaries, the company is engaged in precious metal sales to its clients, including arranging delivery and storage of precious metals for its clients, coin retailing, and lending. Goldmoney clients located in over 200 countries hold over $2.8 billion in precious metal assets. The company’s operating subsidiaries include: Goldmoney.com, SchiffGold.com and Lend & Borrow Trust. In addition to the Company’s principal business segments, the Company holds a significant interest in Menē Inc., which crafts pure 24-karat gold and platinum investment jewelry that is sold by gram weight. Through these businesses and other investment activities, Goldmoney gains long-term exposure to precious metals.

Mako Mining (TSX:MKO.V) is a publicly listed gold mining, development and exploration firm. The Company is developing its high-grade San Albino gold project in Nueva Segovia, Nicaragua. Mako's primary objective is to bring San Albino into production quickly and efficiently, while continuing exploration of prospective targets in Nicaragua

New Stocks added to Energy stocks directory:

Indonesia Energy Corporation (NYSE American:INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC's principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California

New Stocks added to eSports stocks directory:

Gamesquare Esports Inc. (CSE:GSQ.C) Formerly Magnolia Colombia Ltd. - operates an esports agency supported by complementary media and technology to support a cast of influencers, players and on-screen talent in the gaming sector.

New Stocks added to Cannabis stocks directory:

Canbud Distribution Corporation (CSE: CBDX) is an early stage Canadian science and technology based vertically integrated global cannabis and hemp cannabinoids ("CBD") clone to consumer company. The Corporation, through its subsidiaries, holds three industrial hemp licenses for the purposes of supplying the global market with medicinal and wellness cannabidiol and other cannabinoid-based products on leased lands located in McKellar, Ontario, Kettleby, Ontario and Lakefield, Ontario. Each hemp licence allows the growing and harvesting of hemp CBD flowers for processing into CBD and other cannabinoids extracts.

New Stocks added to Cleantech stocks directory:

BioHiTech Global (NasdaqGS: BHTG) is a technology services company focused on providing cost-effective solutions that improve environmental outcomes. Our technologies for waste management include the patented processing of municipal solid waste into a valuable renewable fuel, biological disposal of food waste on-site, and proprietary real-time data analytics tools to reduce food waste generation. When used individually or in combination, our solutions lower the carbon footprint associated with waste transportation and can reduce or virtually eliminate landfill usage. In addition, we distribute a patented technology that achieves high-level disinfection of spaces such as classrooms, hotel or hospital rooms and other enclosed areas to combat the spread of viruses and bacteria without the use of harsh chemicals. Our unique solutions enable businesses, educational institutions and municipalities of all sizes to solve everyday problems in a smarter and more cost-effective way while reducing their impact on the environment.

New stocks added to Tech stocks directory:

Yatra Online, Inc. (Nasdaq: YTRA) is the parent company of Yatra Online Pvt. Ltd. which is based in Gurugram, India and is India's leading Corporate Travel services provider with 700+ Corporate customers and one of India's leading online travel companies and operates the website Yatra.com. The company provides information, pricing, availability, and booking facility for domestic and international air travel, domestic and international hotel bookings, holiday packages, buses, trains, in city activities, inter-city and point-to-point cabs, homestays and cruises. As a leading platform of accommodation options, Yatra provides real-time bookings for more than 108,000 hotels in India and over 1,500,000 hotels around the world.

New Stocks added to Real Estate stocks directory:

Xinyuan Real Estate (NYSE: XIN) is an NYSE-listed real estate developer and property manager primarily in China and recently in other countries. In China, Xinyuan develops and manages large scale, high quality real estate projects in over ten tier one and tier two cities, including Beijing, Shanghai, Tianjin, Zhengzhou, Jinan, Qingdao, Chengdu, Xi'an, Suzhou, Dalian, Zhuhai and Foshan. Xinyuan was one of the first Chinese real estate developers to enter the U.S. market and over the past few years has been active in real estate development in New York. Xinyuan aims to provide comfortable and convenient real estate related products and services to middle-class consumers.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.

Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Wednesday, 14 October 2020

Investorideas.com - Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry October 5th - October 9th, 2020

Investorideas.com - Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry October 5th - October 9th, 2020

www.investorideas.com - news that inspires big ideas

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 481 (CSE: $PRMO.C) (TSXV: $ENW.V) (CSE: $IPOT.C) (TSX: $FAF.TO) (OTCQX: $FFLWF)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 481 (CSE: $PRMO.C) (TSXV: $ENW.V) (CSE: $IPOT.C) (TSX: $FAF.TO) (OTCQX: $FFLWF)

Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland

Delta, Kelowna, BC, October 14, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/101420-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10141PRMO-ENW-IPOT-FAF-FFLWF-CSUI.asp

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few public company announcements.

PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) announced entering into a non-binding letter of intent with MedCanBiotechnologies Inc. who will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms (commonly known as Magic Mushrooms).

Health Canada (HC) has recently shifted towards psychedelic-assisted psychotherapies in safe, controlled environments as acceptable treatment options.

Pursuant to Section 56 exemption from the Canadian Drugs and Substances Act to treat anxiety associated diagnoses,MEDCAN BIOTECH will apply to Health Canada to receive approval under the Controlled Drug and Substances Act to allow MEDCAN BIOTECH to conduct research in order to effectively standardize the extraction of psilocybin from mushrooms.

The Health Canada permit by MEDCAN BIOTECH will allow it to develop and license intellectual property (IP) exclusively for further product development by PRIMO via chemo-typing and geno-typing of 5 different mushrooms to understand their properties.

MEDCAN BIOTECHwill proceed to patent methods of analysis and results on behalf of PRIMO, whereby data generated will be used in the production of nutraceutical products.

All IP and products developed as a result of the analysis will become the property of PRIMOfor their exclusive use.

Psychedelic research focused on psychedelic medicine and psychedelic drugs have demonstrated that these substances have potential for treating ailments including anxiety, addiction, depression, substance dependency, attention deficit hyperactivity disorder and even post-traumatic stress disorder.The data produced can be used to generate premium natural health mushroom nutraceutical products. Genotyping can be used for the identification and labeling of different varieties of psilocybin mushrooms.

EnWave Corporation (TSX-V:ENW) announced today that it has signed a Technology Evaluation and License Option Agreement with an American industrial hemp producer to evaluate the potential commercial use of the Company’s proprietary Radiant Energy Vacuum (“REV™”) dehydration technology. During the term of the TELOA, the Hemp Producer will pay a monthly evaluation fee and have the exclusive option to license REV™ technology for

use in the State of Illinois to dehydrate hemp products for cannabidiol (“CBD”) extraction.

If REV™ demonstrates its proven ability to produce dried hemp with zero degradation of CBD content, the Hemp Producer will be able to leverage EnWave’s patented dehydration platform to improve processing efficiencies and lower their cost of CBD production. If the evaluation is deemed successful by the Hemp Producer, EnWave will aim to sign a royalty-bearing commercial license agreement and an Equipment Purchase Agreement with the Hemp Producer committing to the purchase of REV™ machinery.

EnWave holds a robust intellectual property portfolio spanning numerous international markets and has licensed REV™ technology to more than forty companies operating in eighteen countries worldwide.

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF), an Israel-based company focused on becoming a premier low cost, high quality cannabis producer, announced that the government of Israel has officially enacted the legislation for the export of medical cannabis, clearing the way for sales abroad that the government expects could generate more than 1 billion shekels ($273 million) in annual revenue.

Economy Minister Eli Cohen gave final approval for the exports more than a year after the cabinet initially supported the legislation. Within Israel, medical use of cannabis is permitted with recreational use largely decriminalised. The ministry reports about 70,000 Israelis currently use medical cannabis consuming an estimated 25 tonnes per year. If this growth trend continues, Israel could see a market of over 200,000 medical patients consuming 85 tonnes per year within the next two years.

As reported by Reuters, Hagit Weinstock, co-founder of the Weinstock-Zehavi & Co. law firm and a pioneer of cannabis regulation in Israel stated, “There are many investments that we are expected to see happening now, because investors were waiting for this approval.”

According to recent reports, the Israeli Ministry of Health has launched a new pilot program whereby medical cannabis producers will be approved to export medical cannabis, subject to concurrent product availability to Israeli patients at a fixed discount price of NIS14 per gram (CAD$5.50 per gram) for patients over 21 years old, and NIS10 (CAD$4.00 per gram) for those patients under 21 years old.

Previous reports have outlined how Israel has struggled with cannabis product shortages, as well as complaints about price and quality, which led to the country becoming one of the world’s largest importers of medical cannabis. The pilot program is planned for an initial three-month period during which the specific medical cannabis products to be provided in Israel and made available for export are at the individual producer’s discretion.

Company COO Matt Chatterton notes, “Todays news is a win-win for both the medical patients in Israel and the domestic producers. Export licensing will be a huge economic driver for the licensed producers and an incentive for investment that should spur rapid growth across the industry. The government’s plan to ensure subsidies for the domestic market will see supply finally catch up to demand along with stabilization of the supply chain through improved product processing and quality assurance that is required for entry into export markets. Its been an extensive process to get to where we are today, but with todays announcement we find ourselves in great shape as we continue to build our company and shareholder value in Israel.”

Fire & Flower Holdings Corp. (TSX: FAF) (OTCQX: FFLWF) and its wholly-owned subsidiary Fire & Flower Inc. today announced the launch of a private-label brand collaboration with Decibel Cannabis Company Inc's, premium cannabis brand "Qwest".

The brand collaboration is anticipated to launch on October 15, 2020 in the province of Saskatchewan. Decibel will manufacture, package and ship the private-label products to Open Fields Distribution, Fire & Flower's wholly-owned Saskatchewan distribution business.

The initial product launch will include a pre-rolled format and the Company may look to expand the offering to other products in the future. Spark Perks™ members will receive special member-only pricing and exclusive early access when the products are available in retail stores this week.

"We are pleased to announce this curated product offering to our customers. Qwest products are in high demand in the premium cannabis product category and our collaboration on these private label products will deliver high quality and value to the Fire & Flower customer," shared Nadia Vattovaz, Executive Vice President, Operations and Chief Financial Officer of Fire & Flower. "Our ability to work directly with licensed producers, though our wholesale business, Open Fields Distribution in the province of Saskatchewan demonstrates how this province is leading the Canadian cannabis industry and we believe other provinces should look to how this model can best serve consumers and help eradicate the illegal and unregulated market."

"Decibel is excited to partner with Canada's leading retailer to launch a series of premium pre-rolls, exclusively for Fire & Flower customers," said Adam Coates, Chief Growth Officer of Decibel. "This collaboration allows Qwest the opportunity to provide craft cannabis to a group of new customers while also offering value to Fire & Flower Spark Perks members."

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Tuesday, 13 October 2020

Investorideas.com - Cannabis Stock News: Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) Receives Standard Processing License for Richmond, BC Greenhouse Facility

Investorideas.com - Cannabis Stock News: Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) Receives Standard Processing License for Richmond, BC Greenhouse Facility

Get the latest Cannabis and Hemp stock news from www.investorideas.com

about investorideas.com

About Investorideas.com - Big Investing Ideas Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Cannabis stock news for investors

Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Friday, 16 October 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 483-Review of two years as we approach the anniversary of legalization in Canada

Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland

New #Stocks to watch - Biotech (NasdaqGS: $KTRA), Mining (TSX: $MKO.V), Energy (NYSE American: $INDO), eSport (CSE: $GSQ.C), Cannabis (CSE: $CBDX.C), Cleantech (NasdaqGS: $BHTG)

Wednesday, 14 October 2020

Investorideas.com - Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry October 5th - October 9th, 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 481 (CSE: $PRMO.C) (TSXV: $ENW.V) (CSE: $IPOT.C) (TSX: $FAF.TO) (OTCQX: $FFLWF)

Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland

Tuesday, 13 October 2020

Investorideas.com - Cannabis Stock News: Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) Receives Standard Processing License for Richmond, BC Greenhouse Facility

Public Support for Legalization Remains Strong, Despite Narrow Shortcomings in Challenging State Elections

about investorideas.com

Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks